-
Cell Research: Xiao Junyu/Xie Xiaoliang collaborated to discover a potent and fully human broad
Time of Update: 2021-09-11
Recently, Peking University's School of Life Sciences, Beijing Future Genetic Diagnosis Advanced Innovation Center (ICG), Peking University and Tsinghua Joint Center (CLS) Xiao Junyu and Xie Xiaoliang team cooperated and published the title: Structures of SARS-CoV in Cell Research .
-
The study found that a potent inhibitor targeting the SARS-CoV-2 main protease can be identified in vitro
Time of Update: 2021-09-10
The relevant research results were published in the PNAS journal on September 7, 2021, with the title of the paper "DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors" .
-
Science: Super potent antibody mixture blocks the new coronavirus from attaching to host cells
Time of Update: 2020-10-05
In a new study, researchers from the United States, France, Belgium and Italy found that a super-powerful antibody mixture from recovering COVID-19 patients identified and blocked the infection complex of the pandemic coronavirus and prevented it from entering cells.
-
Science: Super potent antibody mixture blocks the new coronavirus from attaching to host cells
Time of Update: 2020-09-30
addition to preventing SARS-CoV-2 from entering host cells, the presence of these antibodies appears to trigger anti-infection effects on other immune cells, which remove the virus when they arrive.
-
Breakthrough drug for cholestasis! Phase III of the potent ileal bile acid transporter inhibitor
Time of Update: 2020-09-26
results showed that the study reached two main endpoints: odevixibat significantly reduced bile acid response (SBA, p-0.003), significantly improved skin itching (p-0.004), and had a single-digit diarrhea rate compared to placebo.
-
Breakthrough drug for cholestasis! Phase III of the potent ileal bile acid transporter inhibitor
Time of Update: 2020-09-26
results showed that the study reached two main endpoints: odevixibat significantly reduced bile acid response (SBA, p-0.003), significantly improved skin itching (p-0.004), and had a single-digit diarrhea rate compared to placebo.
-
Potent double bet / HDAC inhibitors in the treatment of pancreatic cancer
Time of Update: 2020-02-20
Pancreatic cancer is one of the most aggressive and fatal malignant tumors in human beings The prognosis is very poor, so more effective treatment is urgently needed In order to develop effective new